Teva's Risperdal Gets FDA Nod

It's an oral schizophrenia treatment.
Publish date:


(TEVA) - Get Report

said Thursday that it received a tentative approval from the Food and Drug Administration to market its generic version of Janssen's Risperdal oral solution used in schizophrenia treatment.

Teva said that it expects the final approval on Dec. 29, 2007, when patents expire for the brand product, whose sale in the U.S. were about $66 million for the year ended June. Also upon final approval, the new drug which is in 1 mg/mL form, will be the AA-rated generic equivalent of Risperdal oral solution, the Jerusalem, Israel-based company added.

This story was created through a joint venture between and IRIS.